CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
Gadolinium +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01234870
NCT01234870Phase 3Completed

Comprehensive Evaluation of Ischemic Heart Disease Using MRI

Northwestern University·interventional·Posted Nov 4, 2010·Updated Sep 26, 2014

In Brief

A Phase 3 clinical trial evaluating Gadolinium and Adenosine for Heart Disease, Ischemic and Atherosclerosis, Coronary. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of the study is to assess the diagnostic performance of fully automated motion corrected (MC) first pass myocardial perfusion MRI, compared to the original non-corrected first pass myocardial perfusion images in a cohort of patients with suspected ischemic heart disease, using coronary angiography as the reference standard. It is expected that this improved comprehensive protocol for cardiac MRI be accurate at detecting significant coronary artery disease and may obviate the need for other more expensive and invasive diagnostic tests currently used.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 4, 2010
Enrollment StartJun 1, 2010
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.7 years ago

Interventions

Gadoliniumdrug

Adenosinedrug